Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8⁺ T cell responses against HPV16 oncoproteins.

ABSTRACT: Recent advances in immunotherapy against cancer underscore the importance of T lymphocytes and tumor microenvironment, but few vaccines targeting cancer have been approved likely due in part to the dearth of common tumor antigens, insufficient immunogenicity and the evolution of immune evasion mechanisms during the progression to malignancy. Human papillomaviruses (HPVs) are the primary etiologic agents of cervical cancer and progression from persistent HPV-infection to cervical intraepithelial lesions and eventually cancer requires persistent expression of the oncoproteins E6 and E7. This offers the opportunity to specifically target these virus-specific antigens for vaccine-induced clearance of infected cells before cancers develop. Here we have evaluated the immunogenicity of Adenovirus

SUBMITTER: Cuburu N 

PROVIDER: S-EPMC5805635 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature